

AMENDMENT filed under PCT Article 34

Filed: August 4, 2005

AMENDMENT

To: Commissioner of the Patent Office
(To: Examiner of the Patent Office)

1 Identification of the International Application
PCT/JP2004/015673

2 Applicant

Name: JAPAN SCIENCE AND TECHNOLOGY AGENCY
Address: 1-8, Hon-cho 4-chome, Kawaguchi-shi,
Saitama 332-0012, Japan
Country of nationality: Japan
Country of residence: Japan

3 Agent

Name: (9109) HIRAKI Yusuke
Patent Attorney
Address: Kamiya-cho MT Bldg. 19F,
3-20, Toranomom 4-chome, Minato-ku,
Tokyo 105-0001, Japan

4 Item to be Amended

Claims

5. Contents of Amendment

(1) The term “osteo-/chondro-inducible transcription factor” of claim 1 is amended as “osteo-inducible transcription factor Cbfa1.”

(2) Claim 2 is deleted.

(3) Claim 3 is deleted.

(4) The wording “any one of claims 1 to 3” of claim 4 is amended as “claim 1.”

(5) Claim 5 is deleted.

(6) Claim 6 is added.

(7) Claim 7 is added.

(8) Claim 8 is added.

List of attached documents

(1) “What is claimed is,” page 20 of the English description

What is claimed is:

1. (Amended) An implant consisting of a bioadaptable material comprising an adenoviral or retroviral vector carrying a gene of an osteo-inducible transcription factor Cbfa1.

2. (Deleted)

3. (Deleted)

4. (Amended) The implant according to claim 1, wherein the bioadaptable material is any member selected from the group consisting of hydroxyapatite, α -TCP, β -TCP, collagen, polylactic acid, hyaluronic acid, polyglycolic acid, and a complex of any thereof.

5. (Deleted)

6. (Added) The implant according to claim 4, wherein the bioadaptable material is a porous body consisting of a synthetic polymer composite synthesized from hydroxyapatite, β -TCP, or D, D-L, and L-polylactic acid.

7. (Added) The implant according to claim 6, wherein the bioadaptable material is porous β -TCP.

8. (Added) The implant according to claim 1, 4, 6, or 7, wherein the bioadaptable material comprises an adenoviral or retroviral vector adsorbed thereon.